Evaluation of combinations of 4=-ethynyl-2-fluoro-2=-deoxyadenosine with clinically used antiretroviral drugs

Atsuko Hachiya, Aaron B. Reeve, Bruno Marchand, Eleftherios Michailidis, Yee Tsuey Ong, Karen A. Kirby, Maxwell D. Leslie, Shinichi Oka, Eiichi N. Kodama, Lisa C. Rohan, Hiroaki Mitsuya, Michael A. Parniak, Stefan G. Sarafianos

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Drug combination studies of 4=-ethynyl-2-fluoro-2=-deoxyadenosine (EFdA) with FDA-approved drugs were evaluated by two different methods, MacSynergy II and CalcuSyn. Most of the combinations, including the combination of the two adenosine analogs EFdA and tenofovir, were essentially additive, without substantial antagonism or synergism. The combination of EFdA and rilpivirine showed apparent synergism. These studies provide information that may be useful for the design of EFdA combination regimens for initial and salvage therapy assessment.

Original languageEnglish
Pages (from-to)4554-4558
Number of pages5
JournalAntimicrobial agents and chemotherapy
Volume57
Issue number9
DOIs
Publication statusPublished - 2013 Sep 1

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Evaluation of combinations of 4=-ethynyl-2-fluoro-2=-deoxyadenosine with clinically used antiretroviral drugs'. Together they form a unique fingerprint.

  • Cite this

    Hachiya, A., Reeve, A. B., Marchand, B., Michailidis, E., Ong, Y. T., Kirby, K. A., Leslie, M. D., Oka, S., Kodama, E. N., Rohan, L. C., Mitsuya, H., Parniak, M. A., & Sarafianos, S. G. (2013). Evaluation of combinations of 4=-ethynyl-2-fluoro-2=-deoxyadenosine with clinically used antiretroviral drugs. Antimicrobial agents and chemotherapy, 57(9), 4554-4558. https://doi.org/10.1128/AAC.00283-13